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Back&round: Bayer originally produced aspirin, the first nonsteroidal antiinflammatory drug (NSAID), in 1899. Today, more than 80 billion aspirin tablets
are taken each year in the United States. Along with the popularity of over-thecounter NSAIDs, prescription NSAIDs have become the most widely prescribed
drugs in the world. While the drugs relieve minor pain, decrease fever, and reduce
inflammation, NSAIDs can have serious side effects when used for a long period
of time. The more dangerous side effects include GI ulcers, bleeding, and renal
failure. Since 25% of people who regularly use NSAIDs experience side effects, a
better option for long-term treatment is needed. 1

The negative side effects ofNSAIDs are due to the inhibition of the constitutive
enzyme prostaglandin H2 synthase-l (COX-I). This enzyme is responsible for the
production of prostacyclin, which protects the gastric mucosa, and prostaglandin
E 2, which is needed by the kidneys. The desired effects ofNSAIDs-pain and
fever relief-are brought about by the inhibition ofCOX-2, an isoenzyn1e of
COX-I. COX-2 is induced after an injury or other inflammatory stimulus. It is
responsible for the production of the prostaglandins that lead to inflammation.
The problem with traditional NSAIDs is that these drugs inhibit the "good" COX-

1 enzyme more efficiently than they inhibit the "bad" COX-2. In fact, aspirin is
10 to 100 times more effective against COX-I. 2

This problem has now been solved by the introduction of selective COX-2
inhibitors. One of the first COX-2 inhibitors to be developed is
0-(acetoxyphenyl)hept-2-ynyl sulfide (APHS). This drug is similar to aspirin in
that it inactivates cyclooxygenase by acetylation, but it is 60 times as reactive
against COX-2 and 100 times as selective as aspirin. 3 The first COX-2 inhibitor to
be made available by prescription is celecoxib. The FDA approved celecoxib for
the treatment of adult rheumatoid arthritis and osteoarthritis in December of 1998,
and it is now sold under the trade name Celebrex. Another COX-2 inhibitor
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approved for human use is rofecoxib-referred to commercially as Vioxx. It
produces similar results as the celecoxib, and it is particularly beneficial for people
who are sensitive to sulfonamide drugs. All of these drugs demonstrate the same
analgesic and anti-inflammatory benefits ofNSAIDs without the side effects of
extensive COX-1 inhibition, and research indicates that COX-2 inhibitors may
have even more uses. One probable use for COX-2 inhibitors is in the treatment
of colorectal cancer-people with long-term NSAID use show a 40-50% reduction
in colon cancer risk. 4

Celecoxib

Rofecoxib

Introduction: Cancer of the colon and rectum is the third most diagnosed form of

cancer in United States. Approximately 133,500 new cases of colorectal cancer
were diagnosed in 1996, and in the same year about 54,900 people died as a direct
result of this disease. Thanks to advances in treatment and a greater understanding
of risk factors, the mortality rate for colorectal cancer is decreasing. Some
important risk factors for the disease are age, a family history of colorectal cancer,
sex, and inflammatory bowel disease, but approximately 75% of colon cancer
patients have no known predisposing factors for colorectal cancer. Because these
patients do not exhibit the established risk factors for colorectal cancer, they are
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often not screened for the disease. In fact, the 1992 National Health Interview
Survey found that only 17.3% of the American population above the age of 50 had
been screened that year by fecal occult blood testing, a comn10n screening
method. 5

Increased screening of the general population is needed because the chances of
survival of colorectal cancer are greatly increased by early detection. When the
disease is detected in its early stages, the available treatments are more effective.
If the cancer involves only the bowel wall, the five-year survival rate is about
90%, but this rate falls to less than 10% if the cancer has metastasized. According
to the Agency for Health Care Policy and Research (AHCPR), "the primary
strategy for preventing colorectal cancer deaths is to detect and remove precursors
of colorectal cancer or to detect and treat cancer in its earliest stages". 5

The precursors of colorectal cancer mentioned above are the premalignant
mucosal masses in the colon and rectum----otherwise known as adenomatous
polyps. These colorectal cancer precursors are found in about 25% of the
popUlation by age 50. While the traditional screening methods are effective in
detecting adenomatous polyps, they are often not en1ployed. If the current
screening methods are not being used enough, one solution is to develop new,
easier screening methods. A suggestion of the AHCPR is to use the recent
discoveries in the molecular biology of colorectal cancer to develop new screening
interventions. 5

One recent discovery in the molecular biology of colorectal cancer is the increased
expression of the cyclooxygenase-2 (COX-2) enzyme. In 85% of human
colorectal adenocarcinomas, COX-2 levels are 2 to 50 times greater in the cancer
tissue than in surrounding tissue. 6 And, it is now thought that COX-2 is not
simply present in colorectal cancer; the enzyme is actually needed for the
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development of this cancer.7 As mentioned earlier, the inhibition ofCOX-2 by
NSAIDs, like aspirin, reduces human colorectal cancer risk by 40-50%.6 With a
specific COX-2 inhibitor, the chemopreventive effects ofNSAIDs can be obtained
without the GI side effects. In one study, celecoxib supplementation inhibited the
incidence and multiplicity of colon tumors in rats by 93 and 97% respectively. 8
The chemopreventive benefits of celecoxib have led to its recent approval by the
Food and Drug Administration as a supplement to standard treatment for familial
adenomatous polyposis.

In addition to celecoxib' s chemopreventive benefits, it may serve as a means to
devise a new screening method. Not only is COX-2 found in much higher
concentrations in colorectal cancer adenocarcinomas, the degree of expression
may be related to the severity and stage of the disease. Greater COX-2 expression
is found in larger tumors and in the later stages of the disease, and lymph node
metastasis appears to increase COX-2 expression even further. Higher
concentration of the enzyme also corresponds to decreased survival estimates.

9

Because the COX-2 enzyme is inextricably linked to colorectal cancer, it can be
used as a marker of the disease. This is why the focus of this research, the
synthesis of a radiolabeled celecoxib derivative, might be useful. Labeling a
known COX-2 inhibitor with

1231 should

allow single-photon emission computer

tomography (SPECT) of colorectal cancer. The

123 I

-I abeled celecoxib derivative

would localize in the area of increased COX-2 expression caused by colorectal
adenocarcinomas, and this localization would allow scintigraphy.

Chemistry: The development of a synthetic route to radiolabeled methyl and
methoxy derivatives of celecoxib was originally planned; however, only the
iodinated methoxy derivative was synthesized due to time constraints. The first
synthetic plan required the iodination of 4-methoxyacetophenone, but this reaction
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failed to produce the desired product. Finally, 2-iodoanisole, 1, was chosen as the
starting material for the synthesis.

4-[5-(3-Iodo-4-methoxyphenyl)-3-trifluoromethylpyrazol-l-yl]
benzenesulfonamide, 6, was synthesized from 2-iodoanisole, 1, in four steps as
shown in the Scheme. The reaction sequence could have been limited to three
steps if the remethylation of 4-hydroxy-3-iodoacetophenone, 2, had not been
necessary. After the Friedel-Crafts acylation, the reaction mixture was allowed to
stand at room temperature, which led to demethylation by the Lewis acid,
aluminum chloride. The first step was the Friedel-Crafts acylation of the
iodoanisole 1 to form 3-Iodo-4-methoxyacetophenone, 3, and this was followed by
a Claisen condensation with methyl trifluoroacetate. The 4,4,4-trifluoro-l-(3iodo-4-methoxyphenyl)butane-l,3-dione, 4, formed was then reacted with the
sulfonamide 5 in ethanol to give the iodinated methoxy celecoxib derivative 6.
The final two steps in the Scheme were developed for use in the radioiodination
sequence (which was not carried out due to time constraints).

The key step in the synthesis is the electrophilic iododestannylation of 4-[5-(4methoxy-3-trimethylstannanylphenyl)-3-trifluoromethylpyrazol-l-yl]
benzenesulfonamide, 7. Palladium catalyzed deiodostannylation with
hexamethylditin in dioxane gave the tin precursor 7. The tin compound 7 was
then converted back to the iodinated celecoxib derivative 6 by heating with NaI
and 0.3% peracetic acid. These are the conditions utilized for radioiodine
incorporations involving Na I23!.
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Experimental Section: All the reactions were performed using dry solvents in a

nitrogen atmosphere. The starting materials were purchased from Aldrich
Chemical Company. The products were purified by flash chromatography (Si0 2),
and the IH spectra were taken with a Bruker AC 250 MHz NMR spectrometer.
The chemical shifts are given in parts per million relative to tetramethylsilane.
The melting points were recorded on an Electrothermal Digital Melting Point
Apparatus and are uncorrected.
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4-Hydroxy-3-iodoacetophenone (2)
2-Iodoanisole, 1, (11.7 g, 0.050 mol) was dissolved in dry carbon disulfide (30
mL) and transferred to a 100 mL three-necked flask, equipped with a reflux
condenser, a sealed stirrer unit, and a dropping funnel protected with a Drierite
guard tube. Powdered anhydrous aluminum chloride (15 g, 0.11 mol) was added
and the mixture was heated to gentle refluxing. Acetic anhydride (5.1 g, 0.50 mol)
was added through the dropping funnel. Refluxing was continued for 2 hours, and
the reaction mixture was left at room temperature overnight. The reaction mixture
poured into a mixture of crushed ice (100 g) and concentrated hydrochloric acid
(30 mL). After extraction with ether (2x100 mL), the combined organic extracts
were washed with water and then 10% sodium hydroxide (50 mL). The sodium
hydroxide extract was neutralized with 10% hydrochloric acid (50 mL). The
aqueous portion was extracted with ether (2x 100 mL) and the combined ethereal
extracts were washed sequentially with water and brine. The solution was dried
over anhydrous sodium sulfate and the solvent removed under reduced pressure to
give a pinkish solid. The crude yield was 9.80 g (74.8 %). IH NMR (CDC13): 8,
2.55 (s, 3H), 7.00 (d, 1H), 7.90 (d, 1H), and 8.30 (s, 1H).

3-Iodo-4-methoxyacetophenone (3)
4-Hydroxy-3-iodoacetophenone, 2, (2.70 g, 10.3 mmol) was transferred to a
double necked flask equipped with a reflux condenser and a septum protected with
a Drierite guard tube. The solid w~s dissolved in dry DMF (80 nlL). An excess of
CH31 (2.20 g, 15.5 mmol) and K2C0 3 (2.17 g, 15.5 mmol) was added to the
solution. The reaction mixture was stirred while heating at 60°C for 24 hours.
The mixture was then cooled to room temperature and the solvent removed under
reduced pressure. The solid was purified by column chromatography with 3: 1
petroleum ether/ethyl acetate as the mobile phase to obtain a light yellow product.
The yield of pure product was 2.51 g (88%). IH NMR (CDCh): 8,2.55 (s, 3H),
3.95 (s, 3H), 6.85 (d, 1H), 7.95 (d, 1H), and 8.35 (s, 1H).
9

4,4,4-Trifluoro-l-(3-iodo-4-methoxyphenyl)butane-l,3-dione (4) 10
3-Iodo-4-methoxyacetophenone, 3, (1.17 g, 4.24 mmol) was transferred to a
double necked flask equipped with a reflux condenser and a septum protected with
a Drierite guard tube. The solid was dissolved in dry methanol (2.7 mL) and
sodium methoxide (1.3 mL, 25% solution in methanol) was added. The mixture
was stirred for 5 minutes. Methyl trifluoroacetate (0.60 mL, 5.0 mmol) was then
added. After refluxing for 24 hours, the reaction mixture was cooled to room
temperature. The solvent was removed under reduced pressure and the reaction
was quenched with HCI (3N, 11 mL). The product was extracted with ethyl
acetate (4x7.5 mL), and the extracts dried over anhydrous MgS04 and filtered.
The solvent was removed under reduced pressure, and the brown oil was purified
by column chromatography using a 3: 1 petroleum ether/ethyl acetate mobile
phase. This gave 0.74 g (66%) of a light pink solid. IH NMR (CDCh): 0,4.00 (s,
3H), 6.50 (s, IH), 6.90 (d, IH), 7.95 (d, IH), and 8.40 (s, IH).

4-[ 5-(3-Iodo-4-methoxyphenyl)-3-trifluoromethylpyrazol-l-yI]
benzenesulfonamide (6) 10
Dione 4 (1.27 g, 3.41 mmol) was transferred to a double necked flask equipped
with a reflux condenser and a septum protected with a Drierite guard tube.
The compound was dissolved in dry ethanol (50 mL) and 4sulfonamidophenylhydrazine hydrochloride, 5, (0.90 g, 4.0 mmol) was added to
the solution. The reaction mixture was then refluxed and stirred for 20 hours. The
solution was cooled to room temperature and solvent was removed under reduced
pressure. The product was purified by a flash chromatography column (Si0 2)
using petroleunl ether/ethyl acetate (2: 1) as the mobile phase; a yellow solid was
obtained. The iodinated methoxy celecoxib derivative 6 weighed 1.16 g (65%):
melting point 183-185 °C. IH NMR (CDCh): 0,3.69 (s, 3H), 4.89 (s, 2H), 6.73 (s,
IH), 6.74 (d, IH, J = 8.5 Hz), 7.02 (s, IH, J = 8.5 Hz), 7.47 (d, 2H, J = 8.5 Hz),
7.75 (s, IH), 7.92 (d, 2H, J = 8.5 Hz).
10

4-[5-(4-Methoxy-3-trimethylstannanylphenyl)-3-trifluoromethylpyrazol-l-yl]
benzenesulfonamide (7)
The iodinated methoxy celecoxib derivative 6 (0.55 g, 1.1 mmol) was placed in a
double necked flask equipped with a reflux condenser and flushed with nitrogen.
Anhydrous 1,4-dioxane (12 mL), hexamethylditin (0.540 g, 1.65 mmol), and
tetrakis(triphenylphosphine)palladium (--0.05 g) were added sequentially. The
reaction nlixture was stirred at reflux for 2.5 hours. The solution was cooled to
room temperature and filtered. The solvent was removed under reduced pressure,
and the tin compound 7 was purified by column chromatography with 2: 1
petroleum ether/ethyl acetate as the mobile phase. A yellowish gel was obtained
in a yield of 0.50 g (81 %). IH NMR (CDCh): 0, 0.27 (s with Sn satellites, J Sn-CH

= 54 Hz, 9H), 3.61 (s, 3H), 4.91 (s, 2H), 6.73 (s, IH), 6.75 (d, IH, J = 8.5 Hz),
7.14 (d, IH, J = 8.5 Hz), 7.24 (d, IH), 7.50 (d, 2H, 8.5 Hz) and 7.94 (d, 2H, J = 8.5
Hz).

4-[ 5-(3-Iodo-4-methoxy-phenyl)-3-trifluoromethyl-pyrazol-l-yl]benzensulfonamide (6) from Stannane precursor
To a solution of tin precursor 7 (11. 4 mg, 0.02 mmol) in methanol (0. 3 mL) was
added a solution of sodium iodide (6.0 mg, 0.04 mmol) in water (0. 1 mL).
Peracetic acid (1.0 mL, 0.3 % methanolic solution, 0.04 mmol) was slowly added
and the reaction mixture stirred for 10 min. Excess iodine was decomposed by a
drop of 10% sodium thiosulfate solution. The progression of the reaction was
followed on TLC by comparing with an authentic sample. A major portion of the
starting tin precursor was transformed to the iodo compound 6.

Conclusions: The iodinated methoxy celecoxib derivative 6 was synthesized and
regenerated after stannylation via an oxidative iodination suitable for the
preparation of radioiodinated celecoxib derivative 6. The fact that the iodinated
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compound was easily regenerated indicates that the radiolabeling will be
successful. Radiolabeling experiments are currently in progress.
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